NasdaqGS:GILDBiotechs
Gilead Sciences Data And Label Updates Test HIV And CAR T Valuation
Gilead Sciences and Kite are highlighting new late stage HIV and CAR T cell therapy data, along with regulatory updates, at upcoming medical meetings in 2026.
Gilead Sciences plans to present Phase 3 results for a new single tablet HIV regimen and updates on HIV cure research at CROI 2026.
Kite received an FDA label update for Yescarta that removes a key limitation of use in relapsed or refractory primary central nervous system lymphoma, expanding eligible patients for this CAR T cell...